San Francisco – March 23, 2017 – Cooley advised Aurinia Pharmaceuticals on its $173 million public offering of 25,645,000 common shares, which includes the full exercise of the underwriters’ option to purchase 3,345,000 additional shares.
Aurinia, which is based in Victoria, British Columbia, and trades on The NASDAQ Global Market as “AUPH,” is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high un-met medical need. It is currently developing an investigational drug, voclosporin, for the treatment of lupus nephritis.
In January, Cooley advised Aurinia on its $28.75 million public offering.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.